Top Markets
#1 Status Status +18.91%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.51%
#3 GoPlus Security GoPlus Security +18.45%
#4 Wrapped NXM Wrapped NXM +15.13%
#5 Ontology Gas Ontology Gas +11.65%
#6 DMT-NAT DMT-NAT +8.98%
#7 Pons Pons +8.13%
#8 Provenance Blockchain Provenance Blockchain +7.18%
#9 Nesa Nesa +7.18%
#10 Janction Janction +7.01%
Coin of the day
Status Status
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Clasificación en acciones #33998
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Precio por acción
$0.1502
Última sincronización: 2024-11-04
Capitalización bursátil
$6.43M
Cambio (1 día)
-5.45%
Cambio (1 año)
0.00%
País
US
Comercio Renalytix Plc (RNLX)

Categoría

Healthcare
Ratio P/S de Renalytix Plc (RNLX)
Ratio P/S al August 2026 TTM: 9.85
Según los informes financieros más recientes y el precio de las acciones de Renalytix Plc, el ratio P/S actual (TTM) es 9.85. Al final de 2023, el ratio P/S era 35.27.
Historial del ratio P/S de Renalytix Plc desde 2018 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
2026 (TTM) 9.85 66.11%
2024 5.93 -83.19%
2023 35.27 25.79%
2022 28.04 -96.18%
2021 733.39 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
1.64 -83.31%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
77.67 688.51%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
0.84 -91.45%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
6.37 -35.29%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
- -
US